Decompensation-free survival improved in patients with cirrhosis and portal hypertension who received beta-blockers versus placebo, largely due to a decrease in ascites.
The primary outcome of the retrospective cohort study was postcolonoscopy colorectal cancer within three years, defined as colorectal cancer diagnosed within six and 36 months after negative findings on index colonoscopy.
Monotherapy for inflammatory bowel disease (IBD) with an immunosuppressive agent was associated with a lower risk of serious infection than a tumor necrosis factor (TNF) antagonist alone or an anti-TNF plus an immunosuppressive agent, according to a
Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
Based on the results, study authors suggested expanding colorectal cancer (CRC) screening to patients 45 years of age, but an accompanying editorial expressed concern that the risks could outweigh the benefits in the general population.
Researchers analyzed eight studies with 353 patients to assess the effect of low-molecular-weight heparin or warfarin on recanalization, thrombosis progression, and bleeding.
In 19 randomized controlled trials of 6,261 hospitalized patients on antibiotics, the incidence of C. difficile was 1.6% among patients taking probiotics compared to 3.9% in controls.
Mean procedure time per lesion was significantly shorter with cold snare polypectomy and anticoagulants, whereas the mean hospitalization period was longer in patients receiving hot snare polypectomy and heparin bridging.
A case-control study found that patients who developed colon cancer, particularly in the proximal colon, were more likely to have taken antibiotics, whereas antibiotic use was not associated with increased risk of rectal cancer.
A retrospective trial showed no increase in new corticosteroid therapy or disease-related hospitalization or surgery among patients who discontinued 5-aminosalycilate (5-ASA) therapy when initiating an anti-tumor necrosis factor (anti-TNF) agent.